Latest news
AbCellera Biologics (ABCL) Is Up 21.4% After First Phase 2 Readout For Novel NK3R Antibody – Has The Bull Case Changed? - simplywall.stsimplywall.st · Sun, 09 Aug 2026 00:34:29 GMTAbCellera (ABCL) Stock Surges 6% on Menopause Treatment Phase 2 Data Reveal - BlockonomiBlockonomi · Sat, 08 Aug 2026 14:07:48 GMTAbCellera Reports Q2 2026 Business Results - Business WireBusiness Wire · Wed, 05 Aug 2026 20:05:00 GMTHas Canada’s biotech moment finally arrived? - The Globe and MailThe Globe and Mail · Tue, 04 Aug 2026 09:00:00 GMTVertex–AbCellera T‑Cell Engager Alliance Might Change The Case For Investing In Vertex Pharmaceuticals (VRTX) - simplywall.stsimplywall.st · Fri, 31 Jul 2026 04:54:33 GMTAbCellera Biologics (ABCL) Is Down 5.9% After Vertex-Backed T-Cell Engager Collaboration Announcement - simplywall.stsimplywall.st · Thu, 30 Jul 2026 17:20:42 GMTVertex’s latest autoimmune TCE play involves $28M to AbCellera - Fierce BiotechFierce Biotech · Wed, 29 Jul 2026 12:20:42 GMTAbCellera partners with Vertex on autoimmune therapies - Investing.comInvesting.com · Wed, 29 Jul 2026 11:34:36 GMT